Erdafitinib latest purchase price

Erdafitinib is an oral targeted therapy drug mainly used to treat patients with advanced or metastatic urothelial carcinoma (urothelial carcinoma). Urothelial carcinoma is a malignant tumor originating from the urinary system, including the bladder, renal pelvis, ureter and other parts. Erdafitinib may be an effective treatment option for patients who have received platinum-based chemotherapy and have FGFR2 or FGFR3 genetic abnormalities.

Erdafitinib has not yet been launched on the mainland market in my country. Therefore, patients currently cannot purchase the drug through formal domestic channels and need to purchase it from overseas markets. If you pursue original research quality, the Hong Kong version of original research erdafitinib is the first choice, but it is expensive, with a price tag of more than 20,000 yuan, and can only be purchased through pharmacies in the Hong Kong area. On the other hand, foreign generic drugs offer more economical options. For example, the price range of generic erdafitinib produced by Yaopin International in Laos and Bangladesh ranges from a few hundred yuan to more than 2,000 yuan, which significantly reduces the financial burden of patients. It is worth mentioning that these generic drugs are basically the same as the original drugs in terms of pharmaceutical ingredients and therefore have similar therapeutic effects.

Erdafitinib is a tyrosine kinase inhibitor that works by inhibiting the activity of the FGFR (fibroblast growth factor receptor) family. FGFR is an important cell surface receptor that participates in biological processes such as cell growth, differentiation, and angiogenesis. In some people with urothelial cancer, there are abnormal variations in the FGFR2 or FGFR3 genes that can promote tumor growth and spread. The role of erdafitinib is to inhibit tumor growth and metastasis by inhibiting these abnormal FGFR signaling pathways.

Clinical trial data show that erdafitinib shows significant efficacy in some patients with advanced urothelial cancer. In a phase III clinical trial, patients in the erdafitinib group showed improved overall survival and progression-free survival compared with the chemotherapy control group. These data suggest that erdafitinib may provide an effective treatment option for certain patients with advanced urothelial cancer.

However, like all drugs, there are some side effects and safety considerations with erdafitinib. Common side effects include fatigue, nausea, vomiting, diarrhea, rash, etc. In addition, because it inhibits the FGFR signaling pathway, it may cause eye problems such as keratitis and eyelid edema. Therefore, when using erdafitinib, physicians need to weigh the possible benefits and risks and closely monitor the patient's response.